Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials

$3,495.00

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectious vaccines partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
November 2020
Number of pages
350+
Product type
Research report
Available formats
PDF document
Report edition
3
SKU
CP22061

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.  The report also includes adjuvant deals and alliances.

 

This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. 

 

This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2014, including financial terms where available, including over 550 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

The initial chapters of this report provide an orientation of Infectious Vaccines dealmaking and business activities.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Infectious Vaccines dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms. Infectious Vaccines deals since 2014. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 3 provides a review of the leading Infectious Vaccines deals since 2014. Deals are listed by headline value, signed by big pharma, most active Infectious Vaccines dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Infectious Vaccines dealmaking with a brief summary followed by a comprehensive listing of Infectious Vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Infectious Vaccines partnering deals signed and announced since Jan 2014. The chapter is organized by specific Infectious Vaccines technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided organized by Infectious Vaccines partnering company A-Z, deal type definitions and Infectious Vaccines partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Vaccines partnering and dealmaking since Jan 2014.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Vaccines technologies and products.

 

Report scope

 

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide.

 

Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials includes:

 

  • Trends in infectious vaccines dealmaking in the biopharma industry since 2014
  • Analysis of infectious vaccines deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 550 infectious vaccines deal records
  • Identify the most active infectious vaccine dealmakers since 2014
  • The leading infectious vaccines deals by value since 2014
  • Includes adjuvant deals and alliances since 2014

  

In Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific infectious therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Infectious Vaccines Partnering Terms and Agreements 2014 to 2020: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 550 infectious vaccines deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Infectious Vaccines Partnering Terms and Agreements provides the reader with the following key benefits:

 

  • In-depth understanding of infectious vaccines deal trends since 2014
  • Access infectious vaccines deal headline, upfront, milestone and royalty data
  • Analysis of the structure of infectious vaccines agreements with numerous real life case studies
  • Comprehensive access to over 550 links to actual infectious vaccines deals entered into by the world’s biopharma companies, together with real world clause examples
  • Identify leading infectious vaccines deals by value since 2014
  • Identify the most active infectious vaccines dealmakers since 2014
  • Insight into the terms included in infectious vaccines agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in Infectious Vaccines dealmaking


2.1. Introduction
2.2. Infectious Vaccines partnering over the years
2.3. Most active Infectious Vaccines dealmakers
2.4. Infectious Vaccines partnering by deal type
2.5. Infectious Vaccines partnering by therapy area
2.6. Deal terms for Infectious Vaccines partnering
2.6.1 Infectious Vaccines partnering headline values
2.6.2 Infectious Vaccines deal upfront payments
2.6.3 Infectious Vaccines deal milestone payments
2.6.4 Infectious Vaccines royalty rates

 

Chapter 3 – Leading Infectious Vaccines deals

 

3.1. Introduction
3.2. Top Infectious Vaccines deals by value

 

Chapter 4 – Most active Infectious Vaccines dealmakers

 

4.1. Introduction
4.2. Most active Infectious Vaccines dealmakers
4.3. Most active Infectious Vaccines partnering company profiles

 

Chapter 5 – Infectious Vaccines contracts dealmaking directory

 

5.1. Introduction
5.2. Infectious Vaccines contracts dealmaking directory

 

Chapter 6 – Infectious Vaccines dealmaking by technology type

 

Chapter 7 – Partnering resource center

 

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

 

Appendices

 

Appendix 1 – Infectious Vaccines deals by company A-Z

 

Appendix 2 – Infectious Vaccines deals by stage of development

 

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

 

Appendix 3 – Infectious Vaccines deals by deal type

 

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination

 

Appendix 4 – Infectious Vaccines deals by therapy area

 

Appendix 5 – Deal type definitions

 

About Wildwood Ventures

 

Current Partnering
Current Agreements
Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Infectious Vaccines partnering since 2014
Figure 2: Active Infectious Vaccines dealmaking activity since 2014
Figure 3: Infectious Vaccines partnering by deal type since 2014
Figure 4: Infectious Vaccines partnering by disease type since 2014
Figure 5: Infectious Vaccines deals with a headline value
Figure 6: Infectious Vaccines deals with an upfront value
Figure 7: Infectious Vaccines deals with a milestone value
Figure 8: Infectious Vaccines deals with a royalty rate value
Figure 9: Top Infectious Vaccines deals by value since 2014
Figure 10: Most active Infectious Vaccines dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2A, A*STAR’ Institute of Molecular and Cell Biology, ABEC, ABIVAX, ABL Bio, Abnova, Academy of Military Medical Sciences (China), Adaptive Phage Therapeutics, AdaptVac, Adjuvance Technologies, Aduro BioTech, Advaccine Biotechnology, Advanced Biological Laboratories, Advanced BioNutrition, Advent International, Aelix Therapeutics, Aeras, Aethlon Medical, Affinivax, AGC Biologics, Agenus Bio, AIM ImmunoTech, Akers Biosciences, Akshaya Bio, Albany Molecular Research, Aldevron, Algenex, Altimmune, American Gene Technologies, Amyris, AnGes MG, Antigen Discovery, Antitope, Appili Therapeutics, Applied DNA Sciences, Aptimmune Biologics, Aragen Bioscience, Arcturus Therapeutics, Ardigen, Aridis Pharmaceuticals, Ark Animal Health, Artes Biotechnology, Astellas Pharma, AstraZeneca, Avanzcare, Avid Bioservices, Batavia Biosciences, Battelle, Bavarian Nordic, Baxter International, Baylor College, Baylor College of Medicine, Baylor Institute for Immunology Research, Beth Israel Deaconess Medical Center, Bharat Biotech, Bill and Melinda Gates Foundation, Binex, Bintai Kinden, BioClones, BioComo, bioCSL, Biofactura, Bio Farma, Biokinetic Europe, Biomedical Advanced Research and Development Authority, BiondVax, BioNTech, BioSun Pharmed, Biothera Pharmaceuticals, Blue Water Vaccines, Boehringer Ingelheim, Bpifrance, BravoVax, Brickell Biotech, Brighton Biotech, Broad Institute, BTG, Burnet Institute, Butantan Institute, Caliber Biotherapeutics, California Institute for Medical Researc, Calixar, CARB-X, Catalent, Celonic, Center for Genetic Engineering and Biotechnology (Cuba), Centers for Disease Control and Prevention, Cevec Pharmaceuticals, Changchun BCHT Biotechnology, Children's Hospital Boston, Chimeron Bio, China National Biotech Group (CNBG), Cilian, CimCure, CiToxLAB, City College of New York, City of Hope, ClearPath, Clover Biopharmaceuticals, CMC Biologics, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Codagenix, Codiak BioSciences, ContraFect, Corden Pharma, Corgenix Medical, Create Vaccine Company, Crozet BioPharma, Crucell, CryoPort, CSIRO, CSL, CureVac, CVC, Cystron Biotech, Cytiva, Cytovance Biologics, d3 Medicine, Daiichi Sankyo, Dalton Pharma Services, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Department of Defense, Department of Health and Human Services, Diavax Biosciences, Diaxonhit, Dr. Reddy's Laboratories, Duke-NUS Graduate Medical School Singapore, Duke University, Dyadic International, Dynavax Technologies, DynPort Vaccine Company, Eddingpharm, Eli Lilly, Emergent BioSolutions, Emergex Vaccines, Emmes, Emory University, Endo International, Enesi Pharma, Engility, Ennaid Therapeutics, Entos Pharmaceuticals, Epivax, EpiVax Therapeutics, Etna Biotech, Etubics, Evaxion Biotech, EVQLV, Excivion, ExpreS2ion Biotechnologies, Farmacore Biotechnology, Fatro, Federal Ministry of Education and Research (BMBF), Fina Biosolutions, Finlay Institute, Flow Pharma, FluGen, Fortress Biotech, Fosun Pharmaceutical, Foundation for Biomedical Research and Innovation, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Fujifilm, Fujifilm Diosynth Biotechnologies, GAVI Alliance, GC Pharma, GE Healthcare, GeneOne Life Science, Generex Biotechnology, Genetic Immunity, Geneva Foundation, Genexine, Genkyotex, Genocea Biosciences, Genticel, GenVec, George Mason University, Georgia State University Research Foundation (GSURF), Georgia Tech Research Corporation, GeoVax, German Cancer Research Center, German Federal Ministry of Education and Research, German Government, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glide Technologies, Global Health Innovative Technology Fund (GHIT), Government of Canada, Government of France, Government of Israel, Government of Netherlands, Grameen Health, Grand River Aseptic Manufacturing, Guangzhou Institute of Respiratory Disease, Halix, HaloVax, HanaVax, Harro Hofliger, Harvard Medical School, Harvard University, Hawaii Biotech, Healthcare Royalty Partners, Health Decisions, Heat Biologics, HemispheRx Biopharma, Henry M. Jackson Foundation, Horizon 2020, Hoth Therapeutics, Howard Hughes Medical Institute (HHMI), Human Vaccines Project, hVIVO, iBio, IBT Bioservices, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, IDT Biologika, IHI, ILiAD Biotechnologies, Illumina, ImmBio, Immune Design, Immune Targeting Systems, ImmunityBio, Immunomic, ImmunoPrecise Antibodies, Immunotech Laboratories, Immunovaccine, Immuron, Imperial College London, Imutex, Indian Council of Medical Research, Infectious Disease Research Institute (IDRI), InnaVirVax, Innovate UK, Innovative Medicines Initiative (IMI), Innovo, Inovio, Inovio Pharmaceuticals, Inserm, Inserm Transfert, Institute for Bioscience and Biotechnology Research, Institute of Biomedical Research, Institut Pasteur, Integral Molecular, Integrated BioTherapeutics, International AIDS Vaccine Initiative, International Medica Foundation, International Vaccine Institute (IVI), Intravacc, Ippox Foundation, IQVIA, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Israel Investment Center, Italian Government, Janssen Biotech, Janssen Pharmaceuticals, Jenner Institute, Johnson & Johnson, JSC Pharmadis, KAI Research, Kalon Biotherapeutics, Kansas State University, Karolinska Institute, Kemin Industries, Kindred Bio, King Saud University, Kleo Pharmaceuticals, Korea Advanced Institute of Science and Technology, Laboratorios Farmaceuticos Rovi, Laboratorios Liomont, Laboratory of Malaria Immunology and Vaccinology (LMIV), La Jolla Institute for Allergy & Immunology, Laxisam, Leiden University, Leidos, Leukocare, LiteVax, Lonza, Los Angeles Biomedical Research Institute, Louisiana State University, Lumos Pharma, Lund University, Massachusetts General Hospital, Massachusetts Life Sciences Center, Matrivax, McKesson, Medicago, Medical University of Vienna, MediciNova, MediGene, Medigen Vaccine Biologics, MedImmune, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Meridian Life Science, Metaclipse Therapeutics, Mexican National Technology and Science Council, Micron Biomedical, Midatech, Mie University, MilliporeSigma, MinervaX, Ministry of Finance (China), Ministry of Health, Ministry of Health (Israel), Ministry of Health, Labor and Welfare, Ministry of Industry and Information Technology, MMS, Moderna Therapeutics, MSD Wellcome Trust Hilleman Laboratories, Mucosis, Mundo Sano, MyLife Technologies, Mymetics, Myriad RBM, Mytide Therapeutics, NanoBio, NanoPass Technologies, Nanotherapeutics, NantKwest, National Cancer Institute, National Development and Reform Commission, National Health and Family Planning Commission, National Health Research Institute, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Innovation, National Institute of Cholera and Enteric Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Hygiene and Epidemiology, National Institute of Infectious Diseases, National Institute of Vaccines and Medical Biologicals, National Institutes of Health, National Research Council Canada, National Research Council Industrial Research Assistance Program, National Research Council of Canada, Naval Medical Research Center, New Zealand's Foundation for Research, Science and Technology, Noachis Terra, Noble Life Sciences, NovaDigm Therapeutics, Novartis, Novavax, Novo, Oberland Capital, Ohio State University, Ology Bioservices, Oragenics, Organic Vaccines, OSE Immunotherapeutics, Osivax, Oswaldo Cruz Foundation (Fiocruz), Oxgene, Pacific GeneTech, Panacea Biotech, Partnership for Influenza Vaccine Introduction, PATH (Appropriate Technology in Health), PATH Malaria Vaccine Initiative, PaxVax, PDS Biotechnology, PepTcell, Perelman School of Medicine, Pevion, Pfenex, Pfizer, Pharco Pharma, Pharm-Olam International, PharmaJet, Pharma Science, PharmAthene, PnuVax, Pohang University Of Science And Technology, PolyPeptide Group, PPD, Precision NanoSystems, Precision Virologics, Premas Biotech, Probiomed, Profectus Biosciences, Prokarium, Protein Sciences, PT Bio Farma, Public Health Agency of Canada, Public Health England, Public Health Vaccines, Qualtran, Quebec Government, Ragon Institute, Rapid Micro Biosystems, Recipharm, Redbiotec, Refana, ReiThera, Rockefeller University, RSV, Russian Direct Investment Fund, Sabin Vaccine Institute, SAB Therapeutics, Saiba, Sanaria, Sanofi, Sanofi-Pasteur, Sartorius, Scancell, Science 37, Scripps Research Institute, Seattle Biomed, Seattle Children's Hospital, SEEK, Selecta Biosciences, Selexis, Sementis, Seoul National University, Serum Institute of India, Shenzhen Kangtai Biological Products, Shionogi, Shionogi Pharma, Sinergium Biotech, Sinopharm Group Beijing HuaHong, Sinotek-Advocates International Industry Development, Sinovac Biotech, SiO2 Medical Products, SK Bioscience, SK Chemicals, Small Business Innovation Research, SmartPharm Therapeutics, Smiths Medical, Soligenix, Sorrento Therapeutics, Southern Research Institute, Spicona, SRI International, St. Jude Children's Research Hospital, Stanford University, Stellar Biotechnologies, Strategic Vaccines, Sunstone Capital, SutroVax, Symbiosis, Takara Bio, Takeda Pharmaceutical, Takis Biotech, Talem Therapeutics, Technical University of Denmark (DTU), TechnoVax, Texas A&M University, Texas Biomedical Research Institute, Texas Children’s Hospital, TFF Pharmaceuticals, The International AIDS Vaccine Initiative, The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center, Themis Bioscience, The Native Antigen Company, Theraclone Sciences, Therapure Biopharma, Therapyx, Thomas Jefferson University, Tianjin CanSino Biotechnology, TONIX Pharmaceuticals, Translate Bio, Trellis Bioscience, Trianni, TriLink BioTechnologies, Trinity Pharmaceuticals, Truffle Capital, Tulane University, UK Government, Uldic Investment, UMN Pharma, United Nations Children Fund, United States Agency for International Development, Univercells, University of Adelaide, University of Alabama at Birmingham, University of Alberta, University of California, Davis, University of California, San Diego, University of California Berkeley, University of Chicago, University of Copenhagen, University of Edinburgh, University of Georgia, University of Guelph, University of Hawaii, University of Maryland, University of Maryland School of Medicine, University of Massachusetts, University of Miami, University of Miami Miller School of Medicine, University of Montreal, University of Nagasaki, University of Nebraska, University of Oxford, University of Pennsylvania, University of Queensland, University of Saskatchewan, University of Southampton, University of Texas, University of the Witwatersrand, University of Tokyo, University of Toronto, University of Tubingen, University of Washington, University of Wisconsin-Madison, US Army, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, US Department of Agriculture, US Government, Utrecht University, Vaccitech, Valera Pharmaceutical, Valneva, Variation Biotechnologies, Vaxart, Vaxeal, Vaxess Technologies, Vaxil BioTherapeutics, VaxNewMo, Vaxxas, VBI Vaccines, Verndari, Versatope Therapeutics, Vibalogics, Vical, Vigene Biosciences, Viral Hemorrhagic Fever Consortium, Viravaxx, Vir Biotechnology, Viroclinics Biosciences, VirPath, Vivaldi Biosciences, ViveBio, VLP Therapeutics, Voltron Therapeutics, Wageningen University, Walter Reed Army Institute of Research, Washington University in St Louis, WCCT Global, Wellcome Trust, Wistar Institute, World Health Organization, WuXi Biologics, Xenetic Biosciences, Yisheng Biopharma, Zoetis, Zolovax, Zuellig Pharma China, Zydus Cadila, ZYUS Life Sciences

urrent Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.